Thank you Dave Bjork for having me on your podcast and talking about clinical radiation oncology and the many research opportunities we have to bring precision oncology to our patients with curable lung cancer!
We are thrilled to have received funding from the NCI for high-throughput screening and validation of targeted radiosensitizers and biomarker discovery. We are looking forward to collaborating with other investigators in the Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC), which is tasked with accelerating the pace by at which molecular targeted drug/radiation combinations with greater efficacy than in the past are identified.
We are grateful to the Aid for Cancer Research for funding novel research into the biological effects of proton beam therapy. We will dive into the vastly understudied effects of proton radiation, hoping to make precision medicine a reality for proton beam therapy.
We are thrilled to report that we have received funding from the American Lung Association to study how EGFR-mutant lung cancer cells survive treatment with tyrosine kinase inhibitors (TKI). In this project, we will study how tumor cells persist in the presence of TKI and which vulnerabilities they may possess that can be exploited therapeutically. This will be a collaboration with Aaron Hata, MD, PhD as well as Lecia Sequist, MD, in the MGH Cancer Center.
To move forward with this study we are looking for interested postdoc applicants. Please email your resume and letter as soon as possible. http://www.massgeneral.org/careers/jobsearch.aspx # 3021473